**Supplementary Table 1. Baseline characteristics of study population according to diabetes and median fasting plasm glucose**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristics**  | **All** | **Diabetes** | **Median fasting glucose (mmol/l)** |  |
|  |  | **No** | **Yes** | **p** | **<5.6**  | **5.6-6.9**  | **≥ 7**  | **p** | **Missing** |
| N |  | 118 | 51 |  | 90 | 37 | 42 |  |  |
| Age, years | 66 (53-77.5) | 62 (50-77.5) | 71 (61-78) | 0.014 | 62 (48.7-76.2) | 64 (55-79) | 72 (64-82.5) | 0.021 | 0 |
| Sex Male [N (%)] | 118 (69.8) | 75 (70.8) | 43 (68.3) | 0.73 | 55 (61.1) | 28 (75.7)  | 23 (54.8) | 0.14 | 0 |
| Non Caucasian ethnicity [N (%)] | 32 (18.9) | 26 (22) | 6 (11.8) | 0.14 | 21 (23.3) | 5 (13.5) | 6 (14.3) | 0.30 | 0 |
| BMI | 25.9 (23.5-30.2) | 25.6 (23.1-32.3) | 28 (24.7-33.1) | 0.005 | 25.6 (22.8-29.4) | 26.6 (25-29.9) | 27.7 (24.2-31.8) | 0.087 | 56 |
| Smoke [N (%)] | 29 (17.3) | 23 (19.5) | 6 (12) | 0.27 | 19 (21.1) | 7 (18.9) | 3 (7.3) | 0.150 | 1 |
| Previous venous thromboembolism [N (%)] | 9 (5.3) | 6 (5.1) | 3 (5.9) | 0.99 | 3 (3.3) | 3 (8.1) | 3 (7.1) | 0.46 | 0 |
| Previous bleeding [N (%)] | 8 (4.7) | 5 (4.2) | 3 (5.9) | 0.70 | 4 (4.4) | 2 (5.4) | 2 (4.8) | 0.97 | 0 |
| Previous cancer [N (%)] | 13 (7.7) | 9 (7.6) | 4 (7.8) | 0.99 | 9 (10) | 1 (2.7) | 3 (7.1) | 0.37 | 0 |
| Comorbidities [N (%)] |  |  |  |  |  |  |  |  | 0 |
| * Hypertension
 | 77 (45.6) | 47 (39.8) | 30 (58.8) | 0.029 | 36 (40) | 18 (48.6) | 23 (54.8) | 0.26 |
| * Diabetes
 | 51 (30.2) | 0 (0) | 51 (100) | - | 3 (3.3) | 6 (16.2) | 42 (100) | 0.001 |
| * Coronary Artery Diseases
 | 23 (13.6) | 16 (13.6) | 7 (13.7) | 0.99 | 12 ( 13.3) | 7 (18.9) | 4 (9.5) | 0.47 |
| * Active Cancer
 | 20 (11.8) | 14 (11.9) | 6 (11.8) | 0.99 | 13 (14.4) | 3 (8.1) | 4 (9.5) | 0.52 |
| * COPD
 | 19 (11.2) | 12 (10.2) | 7 (13.7) | 0.60 | 8 (8.9) | 5 (13.5) | 6 (14.3) | 0.59 |
| * Chronic Kidney Disease
 | 18 (10.7) | 9 (7.6) | 9 (17.6) | 0.062 | 7 (7.8) | 3 (8.1) | 8 (19) | 0.13 |
| * Haematological diseases
 | 15 (8.9) | 11(9.3) | 4 (7.8) | 0.99 | 8 (8.9) | 3 (8.1) | 4 (9.5) | 0.98 |
| * Hepatopathy
 | 7 (4.1) | 3 (2.5) | 4 (7.8) | 0.2 | 1 (1.1) | 2 (5.4) | 4 (9.5) | 0.071 |
| * Rheumatic disease
 | 6 (3.6) | 3 (2.5) | 3 (5.9) | 0.37 | 3 (3.3) | 0 (0) | 3 (7.1) | 0.23 |
| Preadmission treatment [N (%)] |  |  |  |  |  |  |  |  | 0 |
| * ACE-inhibitor therapy
 | 31 (18.3) | 18 (15.3) | 13 (25.5) | 0.132 | 16 (17.8) | 6 (16.2) | 9 (21.4) | 0.82 |
| * Antiplatelet therapy
 | 24 (14.2) | 13 (11) | 11 (21.6) | 0.092 | 9 (10) | 7 (18.9) | 8 (19) | 0.25 |
| * Anticoagulant therapy
 | 31 (18.3) | 19 (16.1) | 12 (23.5) | 0.28 | 12 (13.3) | 8 (21.6) | 11 (26.2) | 0.17 |
| * + DOACs
 | 10 (5.9) | 6 (5.1) | 4 (7.8) | 0.49 | 6 (6.7) | 1 (2.7) | 3 (7.1) | 0.64 |
| * + OAT
 | 5 (3) | 3 (2.5) | 2 (3.9) | 0.64 | 1 (1.1) | 2 (5.4) | 2 (4.8) | 0.31 |
| * + LMWH
 | 16 (9.5) | 10 (8.5) | 6 (11.8) | 0.57 | 5 (5.6) | 5 (13.5) | 6 (14.3) | 0.18 |
| * Immunosuppression
 | 4 (2.4) | 4 (3.4) | 0 (0) | 0.32 | 4 (4.4) | 0 (0) | 0 (0) | 0.17 |
| * Steroid
 | 13 (7.7) | 11 (9.3) | 2 (3.9) | 0.35 | 9 (10) | 2 (5.4) | 2 (4.8) | 0.48 |
| * Antihyperglycemic agents
 |  |  |  |  |  |  |  |  |
| * + Metformin
 | 20 (11.9) | 0 (0) | 20 (40) | <0.001 | 1 (1.1) | 6 (16.2) | 13 (31.7) | <0.001 |
| * + Sulfonylureas
 | 6 (3.6) | 0 (0) | 6 (12) | <0.001 | 1 (1.1) | 0 (0) | 5 (12.2) | 0.003 |
| Gliclazide | 4 (2.4) | 0 (0) | 4 (8) | 0.007 | 0 (0) | 0 (0) | 4 (9.8) | 0.002 |
| Glibenclamide | 1 (0.6) | 0 (0) | 1 (2) | 0.30 | 0 (0) | 0 (0) | 1 (2.4) | 0.21 |
| Glimepiride | 1 (0.6) | 0 (0) | 1 (2) | 0.30 | 1 (1.1) | 0 (0) | 0 (0) | 0.65 |
| * + Repaglinide
 | 1 (0.6) | 0 (0) | 1 (2) | 0.30 | 0 (0) | 1 (2.7) | 0 (0) | 0.17 |
| * + DPP-4 inhibitors
 | 3 (1.8) | 0 (0) | 3 (6) | 0.025 | 0 (0) | 0 (0) | 3 (7.3) | 0.009 |
| * + SGLT2 inhibitors
 | 1 (0.6) | 0 (0) | 1 (2) | 0.30 | 0 (0) | 1 (2.7) | 0 (0) | 0.17 |
| * Insulin
 | 10 (6) | 0 (0) | 10 (20) | <0.001 | 1 (1.1) | 0 (0) | 9 (22) | <0.001 |

COPD chronic obstructive pulmonary disease; ACE angiotensin-converting enzyme; DOACs: direct oral anticoagulants;LMWH: Low-molecular-weight heparin; OAT: warfarin/acenocoumarol

**Supplementary Table 2. Outcomes and laboratory values according to diabetes and median fasting plasma glucose**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristics**  | **All** | **Diabetes** | **Median fasting glucose (mmol/l)** |  |
|  |  | **No** | **Yes** | **p** | **<5.6** | **5.6-6.9** | **≥ 7** | **p** | **Missing** |
| N |  | 118 | 51 |  | 90 | 37 | 42 |  |  |
| **Outcomes** |  |  |  |  |  |  |  |  |  |
| Median time from symptoms to admission | 6 (1-11) | 7 (1-12.5) | 5 (1-8) | 0.33 | 7 (0.75-12.2) | 7 (1-12.5) | 5 (1.7-7.5) | 0.77 | 0 |
| Median follow up, days (95%CI) | 222 (211-232) | 220 (209-230) | 231 (214-247) | 0.69 | 213 (192-233) | 231 (217-244) | 231 (215-246) | 0.62 | 0 |
| Hospital stay, days | 17 (8-31) | 14.5 (7-30) | 21 (12-35) | 0.040 | 13.5 (7-27.7) | 21 (8-30) | 22.5 (12.7-35.5) | 0.08 | 0 |
| Non-invasive ventilation | 61 (36.1) | 33 (28) | 28 (54.9) | 0.002 | 18 (20) | 20 (54.1) | 23 (54.8) | <0.001 | 0 |
| Invasive ventilation (ICU) | 23 (13.6) | 11 (9.3) | 12 (23.5) | 0.025 | 5 (5.6) | 7 (18.9) | 11 (26.2) | 0.003 | 0 |
| Death | 35 (20.7) | 15 (12.7) | 20 (39.2) | <0.001 | 9 (10) | 7 (18.9) | 19 (45.2) | <0.001 | 0 |
| Adverse outcome (death and/or Invasive ventilation) | 50 (29.6) | 24 (20.3) | 26 (51) | <0.001 | 13 (14.4) | 12 (32.4) | 25 (59.5) | <0.001 | 0 |
| **Hospital treatment [N (%)]** |  |  |  |  |  |  |  |  |  |
| Antibiotic treatment | 114 (67.5) | 73 (61.9) | 41 (80.4) | 0.02 | 57 (63.3) | 23 (62.2) | 34 (81) | 0.098 | 0 |
| Hydroxychloroquine | 109 (64.5) | 78 (66.1) | 31 (60.8) | 0.6 | 56 (62.2) | 28 (75.7) | 25 (59.5) | 0.26 | 0 |
| Antiviral treatment | 56 (33.1) | 39 (33.1) | 17 (33.3) | 0.99 | 25 (27.8) | 17 (45.9) | 14 (33.3) | 0.14 | 0 |
| Steroids | 32 (19) | 23 (19.5) | 9 (18) | 0.99 | 18 (20) | 5 (13.5) | 9 (22) | 0.60 | 0 |
| Biologics | 27 (16) | 17 (14.4) | 10 (19.6) | 0.49 | 11 (12.2) | 6 (16.2) | 10 (23.8) | 0.25 | 0 |
| Oxigen | 115 (68) | 72 (61) | 43 (84.3) | 0.004 | 49 (54.4) | 29 (78.4) | 37 (88.1) | <0.001 |  |
| **Laboratory parameters**  |  |  |  |  |  |  |  |  |  |
| Random fasting glycaemia (mmol/l) |  |  |  |  |  |  |  |  |  |
| * Mean
 | 97 (85-125) | 89 (81-100) | 147 (132-192) | <0.001 | 86 (80-94) | 111 (104- 116) | 159.5 (139-197) | <0.001 | 0 |
| * Max
 | 116 (96-173) | 106 (91-122) | 209 (152-265) | <0.001 | 97.5 (87-113) | 128 (114-153) | 227 (187-282) | <0.001 | 0 |
| * Min
 | 81 (70-97) | 78.5 (68-88) | 108 (82-139) | <0.001 | 75 (675-82) | 90 (81-103) | 120 (88-150) | <0.001 | 0 |
| * SD
 | 16 (9-30) | 13 (7-18) | 46 (25-57) | <0.001 | 11 (6-16) | 20 (13-29) | 49 (32-72) | <0.001 | 0 |
| * N° of determination
 | 3 (2-8) | 3 (2-7) | 3 (2-8) | 0.87 | 4 (2-8) | 3 (2-6) | 3 (2-8) | 0.81 | 0 |
| PaO2/FiO2  | 280 (200-368) | 300 (196-395) | 258 (204-349) | 0.25 | 305 (198-400) | 269 (195-363) | 258 (199-349) | 0.32 | 22 |
| * <300
 | 80 (54.4) | 52 (51) | 28 (62.2) | 0.22 | 37 (48.7) | 20 (58.8) | 23 (62.2) | 0.34 | 22 |
| * <200
 | 39 (26.5) | 30 (29.4) | 9 (20) | 0.31 | 21 (27.6) | 10 (29.4) | 8 (21.6) | 0.72 | 22 |
| Haemoglobin (g/L) | 128.5 (114-144) | 130 (114-146.2) | 126 (114-144) | 0.72 | 129.5 (113.7-144) | 126 (116-149.5) | 131 (114-144) | 0.90 | 1 |
| Lymphocytes (x109/L) | 1 (0.75-1.5) | 1.1 (0.8-1.55) | 1 (0.52-1.37) | 0.15 | 1.1 (0.7-1.6) | 1.1 (0.8-1.6) | 1 (0.8-1.6) | 0.034 | 4 |
| Creatinine (mol/L) | 84.4 (65.4-111.4) | 82.2 (65.4-106.1) | 96.4 (65.4-152) | 0.039 | 77.8 (66.3-101.7) | 91.9 (72.5-109.6) | 97.2 (68-152.9) | 0.018 | 1 |
| Urea (mmol/L) | 13.9 (8.9-22.2) | 11.9 (8.66-19.6) | 18.6 (10.5-33.8) | 0.004 | 11 (8.6-17.8) | 16.4 (8.9-22.8) | 20 (11.4-40.3) | 0.001 | 3 |
| AST (µkat/L) | 0.68 (0.38-1.06) | 0.6 (0.43-0.91) | 0.82 (0.64-1.35) | 0.035 | 0.58 (0.42-1.07) | 0.83 (0.42-1.07) | 0.87 (0.6-1.39) | 0.005 | 1 |
| ALT (µkat/L) | 0.59 (0.35-0.89) | 0.57 (0.33-0.83) | 0.73 (0.45-0.97) | 0.077 | 0.57 (0.3-0.83) | 0.55 (0.40-0.85) | 0.75 (0.5-0.99) | 0.087 | 1 |
| GGT (µkat/L) | 1.14 (0.38-1.32) | 0.68 (0.33-1.25) | 0.83 (0.53-1.61) | 0.094 | 0.65 (0.32-1.17) | 0.92 (0.4-2.1) | 0.83 (0.5-1.25) | 0.21 | 23 |
| LDH (µkat/L) | 5.24 (3.91-7.95) | 5.04 (3.82-8.8) | 6.65 (4.33-8.8) | 0.006 | 0.83 (0.5-1.35) | 4.68 (3.64-6.93) | 5.63 (4.29-9.1) | 0.001 | 5 |
| Albumin (g/L) | 29.2 (24.5-33.37) | 29.2 (24.3-34.6) | 29.1 (25.9-31.1) | 0.63 | 30.7 (246-34.9) | 28.3 (24.3-34.6) | 27.2 (24.6-30.3) | 0.32 | 49 |
| Pro-BNP (ng/L) | 317 (5 (69.5-1573) | 193 (59-910) | 738 (193-2238) | 0.011 | 205 (55-733) | 232 (107-1788) | 826 (174-2306) | 0.035 | 45 |
| Troponin T (g/L) | 15.7 (7.2-44.5) | 12.7 (6-42.6) | 19.5 (11.4-61.55) | 0.078 | 11.6 (5.4-35.3) | 20.6 (9.6-58.22) | 19.5 (9.9-67.45) | 0.038 | 36 |

AST aspartate transaminase; ALT alanine transaminase; LDH lactate dehydrogenase; pro-BNP precursor of the brain natriuretic peptide